Sermorelin or tesamorelin: how the two peptides actually compare

Last updated 2026-07-24

What is the actual difference between sermorelin and tesamorelin?

Both drugs belong to the same family: growth-hormone-releasing hormone (GHRH) analogs. They bind the same pituitary receptor and tell the gland to make and release more growth hormone (GH). Neither one is HGH itself. That's the first thing people get wrong. Sermorelin is a 29-amino-acid fragment of human GHRH, essentially the shortest piece of the natural hormone that still activates the receptor. Tesamorelin is a modified 44-amino-acid GHRH analog with a trans-3-hexenoic acid group added to the front end, which slows its breakdown and gives it a longer working life in the body ^[1]. The practical difference that matters most to a reader deciding between them: tesamorelin has a specific FDA-approved indication, sermorelin currently does not. Tesamorelin (brand name Egrifta, and the newer Egrifta SV) is approved for reduction of excess abdominal fat in HIV patients with lipodystrophy ^[1]. Sermorelin was FDA-approved once, decades ago, under the brand name Geref, for diagnosing and treating growth hormone deficiency in children and for GH-deficiency testing in adults. That product was discontinued by the manufacturer for business reasons, not pulled for a safety problem ^[2]. There is no currently marketed FDA-approved sermorelin product in the US; what's available today is compounded sermorelin from compounding pharmacies, prescribed off-label. So the honest framing is: tesamorelin has a narrow, proven, on-label use. Sermorelin has a broader off-label prescribing pattern (adult GH support, research use) but rests on older data and a discontinued brand rather than an active approval.

Sermorelin vs tesamorelin vs HGH: what's actually different at the mechanism level

HGH (somatropin) is growth hormone itself, injected directly. It bypasses the pituitary entirely and raises GH and IGF-1 levels no matter what your gland is doing. Sermorelin and tesamorelin are GHRH analogs; they only work if your pituitary still has functioning somatotroph cells to stimulate. That's a real ceiling on effect, and it's also the reason GHRH analogs are considered gentler on feedback loops. Because GHRH analogs rely on the pituitary's own pulsatile release machinery, they tend to preserve the natural on/off rhythm of GH secretion rather than flooding the system with a flat, constant level the way exogenous HGH can. Somatostatin, the body's natural brake on GH release, still works normally with GHRH analogs; it doesn't with directly injected HGH. That built-in brake is one argument some prescribers make for GHRH analogs being lower-risk for GH excess. The tradeoff: HGH injections produce a more reliable, more direct rise in IGF-1, which is why HGH (not sermorelin or tesamorelin) is what's approved for pediatric growth hormone deficiency, Turner syndrome, and adult GH deficiency diagnosed by stimulation testing ^[3]. If a person's pituitary is severely damaged or nonfunctional, a GHRH analog will do very little, because there's no gland tissue left to stimulate. For a deeper explainer on how sermorelin stacks up against direct HGH therapy, including dosing philosophy and cost, see sermorelin.

What is tesamorelin actually approved and proven to do?

Tesamorelin's approval is specific and it's worth being precise about it, because a lot of marketing blurs this. The FDA approved Egrifta in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ^[1]. It is not approved for general fat loss, muscle gain, anti-aging use, or athletic performance in the general population. The key trials behind that approval showed measurable visceral adipose tissue (VAT) reduction. In two randomized, double-blind, placebo-controlled phase 3 trials of tesamorelin in HIV-infected patients with lipodystrophy, the drug reduced visceral fat significantly more than placebo over 26 weeks, an effect published in the main trial report in the Journal of Clinical Endocrinology & Metabolism (Falutz et al., 2010, PMID 20375216) ^[4]. That's a real, quantifiable effect, in a specific population, over a specific time frame. It is not evidence that tesamorelin melts fat in people without HIV-associated lipodystrophy, and the FDA label doesn't claim that. Common side effects reported in tesamorelin trials include injection site reactions, joint pain (arthralgia), swelling (edema), and increases in blood sugar; the label carries a warning about hyperglycemia and its use is discouraged in people with active malignancy given GH's growth-signaling effects ^[1]. It's also expensive: Egrifta SV list price runs into the thousands of dollars per month, though the manufacturer has offered patient assistance programs for eligible HIV patients. Outside its approved indication, tesamorelin does get used off-label, sometimes for general adult GH decline or visceral fat reduction in non-HIV patients. That use isn't illegal for a prescriber to consider, but it's off-label, meaning there's far less trial data supporting safety and effectiveness in that broader population.

What is sermorelin actually proven to do, and where's the evidence weaker?

Sermorelin's evidence base is older and thinner than most people assume. The FDA approval that existed (Geref, approved in the 1990s) covered diagnosis of GH deficiency and treatment of pediatric GH deficiency; the manufacturer, Serono, discontinued the branded product years later, and the FDA's own discontinued-drug listing confirms this was a market withdrawal, not a safety-driven recall ^[2]. Today's sermorelin prescribing in adults, for things like general GH support, body composition, sleep, or recovery, is off-label and relies mostly on older, smaller studies from the 1990s plus more recent observational and compounding-pharmacy-driven clinical use. There is no large modern randomized trial establishing sermorelin's effect on things like fat loss, muscle mass, or longevity in healthy adults. That's an honest gap, not a reason to panic, but a reason to keep expectations modest. What older data does show: sermorelin reliably raises GH and IGF-1 levels in people with at least some functioning pituitary tissue, and it's used clinically as a GH stimulation test agent precisely because that response is measurable and consistent ^[3]. What it hasn't been rigorously shown to do, in modern controlled trials, is reverse aging, meaningfully build muscle in healthy adults, or produce dramatic fat loss on its own. For a full rundown of typical protocols and how prescribers think about titrating dose, see the sermorelin dosage chart and the sermorelin dosage calculator.

How do sermorelin and tesamorelin dosing schedules compare?

Both are given as subcutaneous injections, both are typically dosed once daily, and both are usually timed at bedtime because that's when natural GH pulses peak and the drugs work with, not against, that rhythm.

Are sermorelin and tesamorelin safe, and what side effects show up most?

Both drugs share a similar side effect signature because they work the same way: more GH release means more of GH's known downside effects, mainly fluid retention, joint or muscle aches, and some effect on blood sugar and insulin sensitivity. Sermorelin's most commonly reported side effects in older clinical literature and modern off-label use include injection site redness or itching, flushing, headache, and occasionally dizziness. Because it works through the pituitary's own regulatory loop, severe GH excess is less commonly reported with sermorelin than with direct HGH use, though solid modern safety surveillance data in adults is limited. Tesamorelin's FDA label lists arthralgia (joint pain), injection site reactions, peripheral edema, and hyperglycemia/new-onset diabetes risk as the main concerns identified in trials, and it carries specific label language advising caution in patients with active malignancy or diabetic retinopathy history, given growth hormone's role in cell proliferation and glucose metabolism ^[1]. Neither drug should be used by someone with active cancer, and both need blood sugar monitoring if used for any extended period. If you want the long-view safety picture, including what's known and not known about extended use, read sermorelin long-term side effects before starting anything.

Which one is cheaper, and is the price difference justified?

Sermorelin is meaningfully cheaper in almost every case, and the reason isn't quality, it's regulatory status and manufacturing scale. Compounded sermorelin from a licensed compounding pharmacy commonly runs somewhere in the $150-$400/month range depending on dose, region, and whether it's bundled with provider visits. Tesamorelin, sold as a branded, FDA-approved product (Egrifta SV), often lists at $1,500-$4,000+ per month before insurance or manufacturer assistance programs, which exist specifically because the HIV lipodystrophy population it's approved for often struggles to afford that price. Insurance coverage for tesamorelin outside its approved HIV indication is essentially nonexistent; most payers will not cover it for general age-related GH decline or cosmetic fat reduction. Is the price difference justified? Partly. Tesamorelin's price reflects real trial costs, FDA approval costs, and patent-protected branded manufacturing, plus it has a genuine on-label indication with real effectiveness data behind it for that population. But if you're not in the HIV lipodystrophy population the drug was approved for, you're paying branded-drug prices for an off-label use with the same category of evidence gap that sermorelin has, just backed by a somewhat larger dataset from the original trials. For context on where sermorelin sourcing and pricing typically lands and what separates a legitimate compounding pharmacy from a research-chemical seller, see sermorelin peptide near me and sermorelin reviews.

Sermorelin or HGH: when is sermorelin actually the wrong choice?

This is the question most readers actually have, even if they typed in "sermorelin or tesamorelin." Here's the honest answer: sermorelin is the wrong choice when you have significant pituitary damage or failure, because a GHRH analog only works if there's gland tissue left to respond. In that situation, direct HGH replacement is the medically correct choice, not sermorelin, and this is exactly why HGH, not sermorelin, is the FDA-approved therapy for diagnosed adult growth hormone deficiency and pediatric GHD ^[3]. Sermorelin is also the wrong choice if you're expecting HGH-level, fast, dramatic changes in body composition. Its effect is more gradual and depends on your own pituitary reserve, age, and baseline GH pulsatility, all of which decline somewhat with age. If someone is chasing quick, large changes, sermorelin will likely disappoint them, and that gap between expectation and mechanism is where a lot of dissatisfaction with peptide therapy comes from. Where sermorelin is a reasonable choice: adults with mildly low or borderline GH/IGF-1 levels, intact pituitary function, and a preference for a gentler, lower-cost, more physiologic approach who understand the evidence for adult off-label use is limited and the effect will be moderate, not dramatic. Where tesamorelin is the better choice: HIV-associated lipodystrophy specifically, where it has FDA approval and real trial data. Outside that population, tesamorelin's advantage over sermorelin is mainly a slightly more standardized dose and a somewhat larger (though still narrow) trial dataset, not proof of superior real-world outcomes for general adult use.

Can you switch between sermorelin and tesamorelin, or combine them?

Switching is medically straightforward since both act on the same receptor; a prescriber would typically taper one and start the other with a washout period of a few days, mainly to assess response cleanly rather than for any documented interaction risk. Combining them offers no established benefit. Since both compete for and activate the same GHRH receptor, stacking them doesn't meaningfully add up the way combining drugs with different mechanisms might; it mostly just risks additive side effects (joint pain, fluid retention, blood sugar shifts) without added GH release benefit. No clinical guideline or FDA label recommends combination use of sermorelin and tesamorelin. Some clinics do pair a GHRH analog (sermorelin or tesamorelin) with a separate class, a GH secretagogue like ipamorelin, which works through the ghrelin receptor rather than the GHRH receptor. That's a genuinely different mechanism and is the more common "combo" seen in peptide clinics, not sermorelin-plus-tesamorelin.

How do you know which one a prescriber will actually recommend?

A prescriber's choice usually comes down to three questions: what are you being treated for, what will insurance or your budget realistically cover, and what does your lab work show about baseline pituitary function and IGF-1 levels. If you have HIV-associated lipodystrophy specifically, tesamorelin is the FDA-approved, evidence-backed option and most knowledgeable prescribers will lead with it. If you're an adult without that diagnosis looking at general GH support based on labs and symptoms, most prescribers working in this space reach for sermorelin first, because it's lower cost, has a long history of use (even if off-label now), and the risk profile is well understood even without a current FDA-approved product behind it. A legitimate provider will run baseline labs (IGF-1 at minimum, sometimes a GH stimulation test), ask about cancer history and diabetes risk, and set a re-check point at 3 to 6 months rather than just refilling a script indefinitely. That structure, labs before and during, a defined reassessment point, is the actual marker of a provider-reviewed process worth trusting, more than any specific peptide brand name. Sermorelin Co works with a provider-reviewed prescribing process and names its fulfilling pharmacy partner rather than compounding anything itself, which is the model to look for regardless of which peptide you end up on: a real prescriber reviewing real labs, filled by a real licensed pharmacy.

Frequently asked questions

Is tesamorelin stronger than sermorelin?

In the sense that it produces a more sustained GH pulse per dose, yes, tesamorelin's modified structure resists breakdown longer than sermorelin's shorter peptide chain. But 'stronger' doesn't mean better for most people; tesamorelin's proven benefit is specific to HIV-associated lipodystrophy, and outside that population neither drug has strong evidence for dramatic effects.

Is sermorelin the same as HGH?

No. Sermorelin is a GHRH analog that signals your own pituitary to release more growth hormone. HGH (somatropin) is growth hormone itself, injected directly, bypassing the pituitary entirely. Sermorelin only works if your pituitary still has functioning tissue to respond; HGH works regardless of pituitary function.

Why was Geref (branded sermorelin) discontinued?

Geref was discontinued by its manufacturer for business and market reasons, not because of a safety recall or FDA-driven withdrawal. The FDA's discontinued drug product list reflects a company decision to stop marketing it, which is common for older, lower-volume specialty drugs once patents age out and demand shifts to newer therapies.

Is tesamorelin FDA-approved for weight loss in general?

No. Tesamorelin (Egrifta/Egrifta SV) is FDA-approved only for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, bodybuilding, or anti-aging use, and using it off-label for those purposes isn't backed by the same trial data.

Can sermorelin help with weight loss the way tesamorelin can for HIV patients?

Sermorelin has not been shown in large modern trials to produce visceral fat reduction comparable to tesamorelin's HIV lipodystrophy data. Older studies show modest body composition shifts tied to raised IGF-1, but there's no equivalent phase 3 trial backing a specific fat-loss claim for sermorelin the way there is for tesamorelin's approved indication.

Does insurance cover sermorelin or tesamorelin?

Tesamorelin can be covered by insurance specifically for its approved HIV lipodystrophy indication; outside that, coverage is rare. Sermorelin, having no current FDA-approved adult product, is essentially never covered by insurance and is paid out of pocket through compounding pharmacies, usually in the low hundreds of dollars monthly.

What's the difference in how long each drug takes to show results?

Tesamorelin's key HIV lipodystrophy trials measured visceral fat changes over 26 weeks. Sermorelin's effects, based on older and smaller studies plus clinical experience, are typically assessed at 3 to 6 months. Neither works quickly; both depend on cumulative changes in IGF-1 and GH pulsatility, not an immediate effect.

Are there long-term safety studies for either drug in healthy adults?

Long-term data is limited for both, but especially for sermorelin's current off-label adult use, since its original trials were shorter and focused on pediatric GH deficiency or diagnostic testing. Tesamorelin has more sustained trial follow-up in its approved HIV population, but data in healthy adults using it off-label long-term is sparse.

Can you take sermorelin or tesamorelin if you have a history of cancer?

Generally no, or only with extreme caution and oncology clearance. Both drugs raise GH and IGF-1, and IGF-1 signaling is implicated in cell growth pathways. Tesamorelin's FDA label specifically flags caution around active malignancy; the same caution is applied to sermorelin in standard clinical practice even without an identical label warning.

Is compounded sermorelin legal and safe to use?

It's legal when prescribed by a licensed provider and dispensed by a state-licensed or FDA-registered compounding pharmacy, since sermorelin itself isn't a controlled substance. Safety depends heavily on the pharmacy's quality practices; compounded drugs don't go through the same FDA batch-approval process as an approved drug like Egrifta.

Which one has better research backing, sermorelin or tesamorelin?

Tesamorelin has stronger, more recent trial data, but only for its specific approved use in HIV-associated lipodystrophy. Sermorelin's research is older, smaller in scale, and mostly focused on pediatric growth hormone deficiency and diagnostic testing, with adult off-label use resting on thinner, more dated evidence.

Do sermorelin and tesamorelin show up on standard drug tests?

Neither is included in standard employment or medical drug screening panels, which test for substances like opioids, THC, or amphetamines, not peptide hormones. Specialized endocrine testing could detect elevated GH or IGF-1, but that's not part of routine drug testing.

Sources

1. FDA, Egrifta SV (tesamorelin for injection) prescribing information, accessible via FDA Access Data label search: Tesamorelin is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, approved 2010, with trial data showing visceral fat reduction and listed side effects including arthralgia, edema, and hyperglycemia risk
2. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (discontinued product listings): Geref (branded sermorelin) was discontinued from the US market as a manufacturer business decision, not a safety-driven withdrawal
3. NIH, MedlinePlus, Growth Hormone Test: Direct growth hormone (somatropin) replacement, not GHRH analogs, is the standard FDA-approved treatment for diagnosed pediatric and adult growth hormone deficiency, and GH stimulation testing is used to establish that diagnosis
4. Falutz J, et al. 'Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial.' J Clin Endocrinol Metab. 2010, PMID 20375216: Phase 3 tesamorelin trials in HIV lipodystrophy patients showed significant visceral adipose tissue reduction versus placebo over 26 weeks
5. MedlinePlus (NIH National Library of Medicine), Tesamorelin Injection drug information: Tesamorelin injection is described as indicated to reduce excess abdominal fat in HIV patients with lipodystrophy, with common side effects including joint pain and injection site reactions
6. Walker RF. 'Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?' Clin Interv Aging. 2006;1(4):307-308, PMID 18046911: Sermorelin is a growth hormone-releasing hormone analog historically used to test and treat growth hormone deficiency, given as a subcutaneous injection, with discussion of its use in adult-onset GH insufficiency
7. HHS, HIV.gov, HIV and Opportunistic Infections, Coinfections, and Conditions: Patients with HIV-associated lipodystrophy often face affordability barriers for specialty treatments, which is part of why manufacturer patient assistance programs exist for tesamorelin